Abstract
Vemurafenib, a selective BRAF kinase inhibitor, has been found to induce several cutaneous adverse effects, ranging from a keratosis pilaris-like reac......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
